$1.11
+0.00 (+0.00%)
Open$1.11
Previous Close$1.11
Day High$1.14
Day Low$1.10
52W High$1.78
52W Low$0.96
Volume—
Avg Volume54.6K
Market Cap24.87M
P/E Ratio—
EPS$-2.60
SectorBiotechnology
Analyst Ratings
Strong Sell
7 analysts
Price Target
+998.2% upside
Current
$1.11
$1.11
Target
$12.19
$12.19
$8.12
$12.19 avg
$14.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 3.46M | 3.60M | 3.02M |
| Net Income | 357.4K | 374.4K | 370.1K |
| Profit Margin | 10.3% | 10.4% | 12.2% |
| EBITDA | 792.9K | 795.7K | 655.2K |
| Free Cash Flow | 311.9K | 219.4K | 229.2K |
| Rev Growth | +0.8% | +2.8% | +23.9% |
| Debt/Equity | 0.35 | 0.28 | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.87 | -1.20% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $354.05 | +0.63% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.73 | +0.98% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $449.71 | +0.71% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $776.21 | +0.46% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |